Allogene Therapeutics, Inc. Equity Method Investment, Other than Temporary Impairment
Allogene Therapeutics, Inc. (ALLO) reported Equity Method Investment, Other than Temporary Impairment of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Other Income
us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment · last filed 2026-03-12
- Allogene Therapeutics, Inc. equity method investment, other than temporary impairment for the quarter ending 2024-12-31 was $1.96M, a 51.08% decline year-over-year.
- Allogene Therapeutics, Inc. equity method investment, other than temporary impairment for the quarter ending 2023-12-31 was $4.00M.
- Allogene Therapeutics, Inc. equity method investment, other than temporary impairment for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Allogene Therapeutics, Inc. equity method investment, other than temporary impairment for fiscal 2024 was $1.96M, a 72.04% decline from fiscal 2023.
- Allogene Therapeutics, Inc. equity method investment, other than temporary impairment for fiscal 2023 was $7.00M.
- Allogene Therapeutics, Inc. equity method investment, other than temporary impairment for fiscal 2022 was $0.00.
| Period end | Equity Method Investment, Other than Temporary Impairment 3 month | Equity Method Investment, Other than Temporary Impairment 9 month | Equity Method Investment, Other than Temporary Impairment 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | ||
| 2024-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.96M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $7.00M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $3.00M 10-Q · filed 2024-11-07 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |